Lineage Cell Therapeutics, Inc. (LCTX)

ASE – Цена в реальном времени. Валюта: USD

1.33

+0.02 (1.53%)

При закрытии: May 12, 2026, 4:00 PM EDT

1.36

+0.03 (2.26%)

После закрытия: May 12, 2026, 7:59 PM EDT

12.05.2026

Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates

Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.02 per share a year ago.

12.05.2026

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today reported its first quarter 2026 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. “This quarter, we continued to build on our developmental and clinical acc.

05.05.2026

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that it will report its first quarter 2026 financial and operating results on Thursday, May 12, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 12, 2026, at 4:30 p.m. Eas.

04.05.2026

OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that 36-month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), were presented at the Fou.

13.04.2026

Lineage Announces Formation of Scientific Advisory Board

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the formation of a Scientific Advisory Board (SAB) to provide strategic counsel and insights into the development of Lineage's novel cell transplant pipeline, built on the Company's proprietary cell differentiation and expansion platform, AlloSCOPE™.

24.03.2026

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the expansion of its cell transplant pipeline with the launch of COR1, a new corneal endothelial cell (CEnC) therapy program, in preclinical development for the treatment of corneal endothelial disease. Corneal endothelial disease is a progressive,.

06.03.2026

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript

Видео

No Data

There is no data to display

Пресс-релизы

12.05.2026

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

04.05.2026

OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that 36-month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), were presented at the Fou.

13.04.2026

Lineage Announces Formation of Scientific Advisory Board

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the formation of a Scientific Advisory Board (SAB) to provide strategic counsel and insights into the development of Lineage's novel cell transplant pipeline, built on the Company's proprietary cell differentiation and expansion platform, AlloSCOPE™.

24.03.2026

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the expansion of its cell transplant pipeline with the launch of COR1, a new corneal endothelial cell (CEnC) therapy program, in preclinical development for the treatment of corneal endothelial disease. Corneal endothelial disease is a progressive,.

Lineage Cell Therapeutics, Inc. (LCTX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

Lineage Announces Formation of Scientific Advisory Board

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

Lineage Announces Formation of Scientific Advisory Board

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

Lineage Announces Formation of Scientific Advisory Board

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

Lineage Announces Formation of Scientific Advisory Board

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

Search stocks

Lineage Cell Therapeutics, Inc. (LCTX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

Lineage Announces Formation of Scientific Advisory Board

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

Lineage Announces Formation of Scientific Advisory Board

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

Lineage Announces Formation of Scientific Advisory Board

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

Lineage Announces Formation of Scientific Advisory Board

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease